Pharmacological hypoglycemic treatments including PPAR-γ agonists (e.g., pioglitazone) (37), metformin (38), or glucagon-like peptide-1 agonists [e.g., liraglutide (39) or semaglutide (40)] have shown histological improvement in nonalcoholic steatohepatitis (NASH) patients. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.